Filing summary
Period and identity: The filing is an IsoRay, Inc. Form 10-Q for the quarter ended March 31, 2012 (fiscal 2012 third quarter), filed May 14, 2012. This conflicts with the request metadata identifying Perspective Therapeutics and “2011 Q3”; the supplied filing itself identifies IsoRay, Inc.
Financial results
| Metric | Three months ended March 31, 2012 | Nine months ended March 31, 2012 |
|---|---|---|
| Product sales | $1.317 million, down 7% year over year | $3.759 million, down 6% |
| Gross profit / margin | $204,220 / 16% (prior year: $357,426 / 25%) | $469,461 / 12% (prior year: $700,943 / 18%) |
| Operating loss | $762,859 | $2.657 million |
| Net loss | $552,886 | $2.284 million |
| Net loss applicable to common shareholders | $555,544; $0.02 per share | $2.292 million; $0.08 per share |
| Operating cash used | Not separately reported for the quarter | $1.824 million (prior year: $1.808 million) |
- At March 31, cash and cash equivalents were $2.524 million; current assets were $4.007 million and current liabilities $626,107, implying working capital of approximately $3.381 million.
- Total liabilities were $1.439 million, including a $104,905 warrant liability and $708,243 asset retirement obligation. The balance sheet reports no notes payable at March 31.
- Financing provided $2.305 million in the first nine months, chiefly from common-stock offerings. Cash rose $412,143 from June 30, 2011.
Changes and management commentary
- Prostate product sales, the largest source of revenue, declined 11% in both the quarter and nine-month comparison. Management cited market pressure from alternatives such as IMRT and robotic treatments.
- Non-prostate applications partly offset the decline: nine-month brain and lung sales increased, and GliaSite RTS generated $83,780 in nine-month sales. The GliaSite product began U.S. clinical sales during the period.
- Lower sales and largely fixed production costs reduced gross margin. Nine-month R&D expense rose 53% to $573,212, while total operating expenses rose 8% to $3.127 million. Operating loss worsened 21% year over year.
- Quarterly net loss improved year over year, substantially reflecting a $213,095 gain on warrant-liability remeasurement versus a $163,000 loss in the prior-year quarter. The nine-month warrant remeasurement gain was $379,095; it is noncash and depends on valuation assumptions.
- In October and December 2011, the company sold shares and warrants, receiving $2.593 million gross and approximately $2.274 million net proceeds. The company said it had not used these offering proceeds through March 31.
Outlook, risks, and contingencies
- Management stated that approximately $2.32 million of cash and cash equivalents at May 2, 2012 was expected to fund operations and capital needs for at least 12 months, assuming revenue and expenses remained at current levels. Monthly cash operating expenditures averaged approximately $203,000 during the nine-month period.
- Management expected fiscal 2012 capital expenditures below $100,000 and approximately $100,000 in protocol expenses, while noting that unanticipated spending could arise. It planned to pursue GliaSite sales, new and existing customers, and additional treatment applications; profitability and revenue growth were not assured.
- Management anticipated that future financing might require equity issuance, potentially at a discount and dilutive to shareholders; acceptable financing might not be available. The filing warned that without additional capital the company expected to fall below NYSE Amex minimum stockholders’ equity requirements for the quarter ending June 30, 2012, creating delisting risk.
- A dispute with the Lawrence Family Trust over a 1% know-how royalty remained unresolved; binding arbitration could be demanded. The company also reported radioactive-material and product-liability exposures, an asset retirement obligation, and no off-balance-sheet arrangements.
- Management reported effective disclosure controls, while continuing remediation of a material weakness and significant deficiency identified in the prior-year Form 10-K.
Investor verification priorities
- Confirm the issuer and reporting period: the supplied document is IsoRay’s fiscal 2012 third-quarter filing, not a Perspective Therapeutics filing or 2011 Q3 report.
- Assess cash runway against actual subsequent cash use, revenue trends, and the stated 12-month liquidity assumption; verify financing needs and potential dilution.
- Track NYSE Amex equity-listing compliance and any delisting notices or capital-raising developments.
- Evaluate whether GliaSite and non-prostate applications can scale beyond early, physician-influenced sales, and whether gross margins can recover.
- Review the warrant valuation, royalty dispute, radioactive-material obligations, and progress in remediating the previously reported control deficiencies.